SEC Tracker
Get the app

Revolution Medicines RVMD

Revolution Medicines announced Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. RASONQUE generated $198 million in net product revenue for the quarter
  2. FDA approved RASONQUE for metastatic pancreatic cancer on August 26, 2026
  3. CHMP recommended marketing authorization for RASONQUE in the EU
  4. Over 5,000 unique patients received RASONQUE in the U.S. through September 30, 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Revolution Medicines files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Repligen RGEN public float $6.0B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025